[
  {
    "ts": null,
    "headline": "AdvaMed names Jake Leach as chair of diabetes sector",
    "summary": "The Dexcom CEO will lead the lobbying group’s sector representing diabetes tech companies around the world.",
    "url": "https://finnhub.io/api/news?id=1fccdbf7e27f98038669e922d48cf580d2a055c5606d8db589c6faa669aa5254",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771950833,
      "headline": "AdvaMed names Jake Leach as chair of diabetes sector",
      "id": 139201650,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABT",
      "source": "Yahoo",
      "summary": "The Dexcom CEO will lead the lobbying group’s sector representing diabetes tech companies around the world.",
      "url": "https://finnhub.io/api/news?id=1fccdbf7e27f98038669e922d48cf580d2a055c5606d8db589c6faa669aa5254"
    }
  },
  {
    "ts": null,
    "headline": "Personalized Medicine Market Competitive Landscape Report 2025: Company Analysis, Company Profiles, Strategic Developments, Mergers, Product Innovations, Revenue Insights, and Future Forecasts to 2033",
    "summary": "Personalized Medicine Market Poised for Tremendous Growth by 2033The global personalized medicine market, valued at approximately US$ 585.53 billion in 2026, is projected to soar to nearly US$ 1.00 trillion by 2033. A report by Renub Research highlights an impressive CAGR of 7.05% from 2025 to 2033, driven by advances in genomics and biotechnology. Demand is rising for individualized treatments that enhance therapeutic efficacy while reducing side effects. Key players like Abbott Laboratories an",
    "url": "https://finnhub.io/api/news?id=540191c4fe0aa49a2a91396f9a0ea65054ead6dbdbe2599fbc076e84ad860056",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771950600,
      "headline": "Personalized Medicine Market Competitive Landscape Report 2025: Company Analysis, Company Profiles, Strategic Developments, Mergers, Product Innovations, Revenue Insights, and Future Forecasts to 2033",
      "id": 139198888,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABT",
      "source": "Yahoo",
      "summary": "Personalized Medicine Market Poised for Tremendous Growth by 2033The global personalized medicine market, valued at approximately US$ 585.53 billion in 2026, is projected to soar to nearly US$ 1.00 trillion by 2033. A report by Renub Research highlights an impressive CAGR of 7.05% from 2025 to 2033, driven by advances in genomics and biotechnology. Demand is rising for individualized treatments that enhance therapeutic efficacy while reducing side effects. Key players like Abbott Laboratories an",
      "url": "https://finnhub.io/api/news?id=540191c4fe0aa49a2a91396f9a0ea65054ead6dbdbe2599fbc076e84ad860056"
    }
  },
  {
    "ts": null,
    "headline": "Cancer Diagnostics Market Competitive Landscape Report 2025: Key Players Analysis, Profiles, Strategic Developments, Mergers, Product Innovations, Revenue Insights, and Future Forecasts to 2033",
    "summary": "The Cancer Diagnostics Market is set to grow from USD 197.7 billion in 2025 to USD 345.57 billion by 2033, driven by a 7.23% CAGR. Factors like rising cancer incidence, technological advancements in diagnostics, and the importance of early detection are pivotal for this expansion. The market is also fueled by a demand for personalized medicine and enhanced imaging services. Leading companies like Illumina, Abbott Laboratories, and Thermo Fisher Scientific aid this growth through innovations in g",
    "url": "https://finnhub.io/api/news?id=0f090f23c2fd4e1af43df66d3e63e30751355fc39b2da2f76f0122c1c6506a7d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771949760,
      "headline": "Cancer Diagnostics Market Competitive Landscape Report 2025: Key Players Analysis, Profiles, Strategic Developments, Mergers, Product Innovations, Revenue Insights, and Future Forecasts to 2033",
      "id": 139198889,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABT",
      "source": "Yahoo",
      "summary": "The Cancer Diagnostics Market is set to grow from USD 197.7 billion in 2025 to USD 345.57 billion by 2033, driven by a 7.23% CAGR. Factors like rising cancer incidence, technological advancements in diagnostics, and the importance of early detection are pivotal for this expansion. The market is also fueled by a demand for personalized medicine and enhanced imaging services. Leading companies like Illumina, Abbott Laboratories, and Thermo Fisher Scientific aid this growth through innovations in g",
      "url": "https://finnhub.io/api/news?id=0f090f23c2fd4e1af43df66d3e63e30751355fc39b2da2f76f0122c1c6506a7d"
    }
  },
  {
    "ts": null,
    "headline": "Lung Cancer Diagnostics Competitive Landscape Report 2025: Key Players Analysis, Profiles, Strategic Developments, Mergers, Product Innovations, Revenue Insights, and Future Forecasts to 2033",
    "summary": "The Lung Cancer Diagnostics Market is set to expand from US$ 21.74 billion in 2025 to US$ 38.00 billion by 2033, growing at a CAGR of 7.23%. Major growth drivers include increased public access facilities, rise in ambulance services, and higher prevalence of cardiac disorders. Advances in lung cancer detection techniques like chest X-rays, CT scans, and MRIs cater to the demand for early and accurate diagnoses, crucial for effective treatment. Market leaders such as Illumina, Abbott Laboratories",
    "url": "https://finnhub.io/api/news?id=dfcfe20862fbdc93928d26dd3528ca7b65844b162c317dc98fc0d793a68b573d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771949460,
      "headline": "Lung Cancer Diagnostics Competitive Landscape Report 2025: Key Players Analysis, Profiles, Strategic Developments, Mergers, Product Innovations, Revenue Insights, and Future Forecasts to 2033",
      "id": 139198890,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABT",
      "source": "Yahoo",
      "summary": "The Lung Cancer Diagnostics Market is set to expand from US$ 21.74 billion in 2025 to US$ 38.00 billion by 2033, growing at a CAGR of 7.23%. Major growth drivers include increased public access facilities, rise in ambulance services, and higher prevalence of cardiac disorders. Advances in lung cancer detection techniques like chest X-rays, CT scans, and MRIs cater to the demand for early and accurate diagnoses, crucial for effective treatment. Market leaders such as Illumina, Abbott Laboratories",
      "url": "https://finnhub.io/api/news?id=dfcfe20862fbdc93928d26dd3528ca7b65844b162c317dc98fc0d793a68b573d"
    }
  },
  {
    "ts": null,
    "headline": "Hormone Replacement Therapy Market Competitive Landscape Report 2025: Top Players Analysis, Profiles, Strategic Developments, Mergers, Product Innovations and Launches, Sustainability Goals, Revenues",
    "summary": "The Hormone Replacement Therapy (HRT) market is poised to expand significantly from $23.58 billion in 2025 to $38.18 billion by 2033, driven by a CAGR of 6.21%. Key growth drivers include technological advancements, innovations in delivery methods, and rising cases of hormonal disorders. Increased awareness and acceptance of HRT, largely for menopause-related symptoms in women, alongside supportive government policies, further contribute to market growth. The sector sees immense potential, parti",
    "url": "https://finnhub.io/api/news?id=eb43ff69c7c22b310521cf4bc951ee0003642e39641dad783bf7e02ae9847d41",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771934460,
      "headline": "Hormone Replacement Therapy Market Competitive Landscape Report 2025: Top Players Analysis, Profiles, Strategic Developments, Mergers, Product Innovations and Launches, Sustainability Goals, Revenues",
      "id": 139194419,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABT",
      "source": "Yahoo",
      "summary": "The Hormone Replacement Therapy (HRT) market is poised to expand significantly from $23.58 billion in 2025 to $38.18 billion by 2033, driven by a CAGR of 6.21%. Key growth drivers include technological advancements, innovations in delivery methods, and rising cases of hormonal disorders. Increased awareness and acceptance of HRT, largely for menopause-related symptoms in women, alongside supportive government policies, further contribute to market growth. The sector sees immense potential, parti",
      "url": "https://finnhub.io/api/news?id=eb43ff69c7c22b310521cf4bc951ee0003642e39641dad783bf7e02ae9847d41"
    }
  },
  {
    "ts": null,
    "headline": "Point of Care Diagnostics Market Competitive Landscape Report 2025 Featuring Top 5 Players - Sysmex, Abbott Laboratories, Becton Dickinson and Co, Danaher, Quidel Diagnostics",
    "summary": "By 2033, the Point of Care (POC) Diagnostics market is projected to reach a valuation of approximately US$ 105.22 billion, driven by an 8.60% CAGR from 2025. This robust growth is fueled by high demand for rapid and accessible testing, escalating global prevalence of infectious diseases, and breakthroughs in technology. POC diagnostics facilitate immediate results at patient care sites, enhancing clinical decision-making and patient outcomes. Key players leading this market, including Sysmex, Ab",
    "url": "https://finnhub.io/api/news?id=c7dee46660dfb88617b19fd30ff9810656dc2e7d7bb58811acd4694555d9bad7",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771932960,
      "headline": "Point of Care Diagnostics Market Competitive Landscape Report 2025 Featuring Top 5 Players - Sysmex, Abbott Laboratories, Becton Dickinson and Co, Danaher, Quidel Diagnostics",
      "id": 139193296,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABT",
      "source": "Yahoo",
      "summary": "By 2033, the Point of Care (POC) Diagnostics market is projected to reach a valuation of approximately US$ 105.22 billion, driven by an 8.60% CAGR from 2025. This robust growth is fueled by high demand for rapid and accessible testing, escalating global prevalence of infectious diseases, and breakthroughs in technology. POC diagnostics facilitate immediate results at patient care sites, enhancing clinical decision-making and patient outcomes. Key players leading this market, including Sysmex, Ab",
      "url": "https://finnhub.io/api/news?id=c7dee46660dfb88617b19fd30ff9810656dc2e7d7bb58811acd4694555d9bad7"
    }
  },
  {
    "ts": null,
    "headline": "Epilepsy Drugs Market Competitive Landscape Report 2025: Key Players Analysis, Profiles, Strategic Developments, Mergers, Product Innovations, Revenue Insights",
    "summary": "The global epilepsy drugs market is poised for robust growth, estimated to increase from US$ 8.29 billion in 2025 to US$ 11.85 billion by 2033, with a CAGR of 4.57%. Key growth drivers include the rising prevalence of epilepsy, advancements in anti-epileptic medications, and innovative treatment research. Epilepsy drugs, vital for managing seizures, have seen increased global demand due to improved diagnostics and awareness. Major companies like Eisai Co. Ltd., UCB Inc., and Abbott Laboratories",
    "url": "https://finnhub.io/api/news?id=181354cf5075147595c13dffcfe4273e8913258727bfca85d3182dc232a7ef7b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771932720,
      "headline": "Epilepsy Drugs Market Competitive Landscape Report 2025: Key Players Analysis, Profiles, Strategic Developments, Mergers, Product Innovations, Revenue Insights",
      "id": 139193297,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABT",
      "source": "Yahoo",
      "summary": "The global epilepsy drugs market is poised for robust growth, estimated to increase from US$ 8.29 billion in 2025 to US$ 11.85 billion by 2033, with a CAGR of 4.57%. Key growth drivers include the rising prevalence of epilepsy, advancements in anti-epileptic medications, and innovative treatment research. Epilepsy drugs, vital for managing seizures, have seen increased global demand due to improved diagnostics and awareness. Major companies like Eisai Co. Ltd., UCB Inc., and Abbott Laboratories",
      "url": "https://finnhub.io/api/news?id=181354cf5075147595c13dffcfe4273e8913258727bfca85d3182dc232a7ef7b"
    }
  },
  {
    "ts": null,
    "headline": "Genetic Testing Market Competitive Landscape Report 2025: Key Players Analysis, Profiles, Strategic Developments, Sustainability, Launches, Mergers, Product Innovations, Revenue Insights",
    "summary": "The genetic testing market is set to reach USD 49.72 billion by 2033, expanding at a CAGR of 9.79% from USD 23.55 billion in 2025. Key growth drivers include oncology, rare disease diagnostics, and prenatal testing, underscoring genetic testing's critical role in global healthcare. This surge is propelled by technological advancements and rising consumer awareness, with direct-to-consumer testing becoming more accessible. Companies like Abbott, Illumina, and Roche are at the forefront of this ma",
    "url": "https://finnhub.io/api/news?id=e9e4adafbc19a7ea30e380ebde003ee3892f899b3f382488847c95c32a9859d9",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771932600,
      "headline": "Genetic Testing Market Competitive Landscape Report 2025: Key Players Analysis, Profiles, Strategic Developments, Sustainability, Launches, Mergers, Product Innovations, Revenue Insights",
      "id": 139193298,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABT",
      "source": "Yahoo",
      "summary": "The genetic testing market is set to reach USD 49.72 billion by 2033, expanding at a CAGR of 9.79% from USD 23.55 billion in 2025. Key growth drivers include oncology, rare disease diagnostics, and prenatal testing, underscoring genetic testing's critical role in global healthcare. This surge is propelled by technological advancements and rising consumer awareness, with direct-to-consumer testing becoming more accessible. Companies like Abbott, Illumina, and Roche are at the forefront of this ma",
      "url": "https://finnhub.io/api/news?id=e9e4adafbc19a7ea30e380ebde003ee3892f899b3f382488847c95c32a9859d9"
    }
  },
  {
    "ts": null,
    "headline": "Is Abbott Laboratories (ABT) Pricing Reflect Long Term Value After Recent Share Price Weakness",
    "summary": "If you are wondering whether Abbott Laboratories is attractively priced or just fairly valued at current levels, you are not alone. This article will help you put the current share price in context. The stock last closed at US$115.29, with returns of 2.3% over 7 days and 7.3% over 30 days, while year to date and 1 year returns are a 7.2% decline and a 13.0% decline respectively. Recent attention on Abbott has centered on broader healthcare sector sentiment and how large, diversified medical...",
    "url": "https://finnhub.io/api/news?id=860f463232a5b6b4703f362cad3639661556f2dd89571d204553c91b6b1d68f1",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771913181,
      "headline": "Is Abbott Laboratories (ABT) Pricing Reflect Long Term Value After Recent Share Price Weakness",
      "id": 139191739,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABT",
      "source": "Yahoo",
      "summary": "If you are wondering whether Abbott Laboratories is attractively priced or just fairly valued at current levels, you are not alone. This article will help you put the current share price in context. The stock last closed at US$115.29, with returns of 2.3% over 7 days and 7.3% over 30 days, while year to date and 1 year returns are a 7.2% decline and a 13.0% decline respectively. Recent attention on Abbott has centered on broader healthcare sector sentiment and how large, diversified medical...",
      "url": "https://finnhub.io/api/news?id=860f463232a5b6b4703f362cad3639661556f2dd89571d204553c91b6b1d68f1"
    }
  },
  {
    "ts": null,
    "headline": "Russia's war on Ukraine puts women off having children — and that could spell economic disaster",
    "summary": "Four years of war have discouraged Ukrainian and Russian women from having children, and that could impact their economies in the future.",
    "url": "https://finnhub.io/api/news?id=53795300e06e0d4454e6b04b451c0e619690754126ab2762ed8dab8647314a9d",
    "source": "CNBC",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771895025,
      "headline": "Russia's war on Ukraine puts women off having children — and that could spell economic disaster ",
      "id": 139198069,
      "image": "https://image.cnbcfm.com/api/v1/image/108268945-1771917055711-gettyimages-1583281302-uk_20230807_ukr61.jpeg?v=1771917103&w=1920&h=1080",
      "related": "ABT",
      "source": "CNBC",
      "summary": "Four years of war have discouraged Ukrainian and Russian women from having children, and that could impact their economies in the future.",
      "url": "https://finnhub.io/api/news?id=53795300e06e0d4454e6b04b451c0e619690754126ab2762ed8dab8647314a9d"
    }
  }
]